Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD4 | P01730 | 8/20 | 0.89 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7616547 | 0.94 | CD4 (1.00) | CD4SORT1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4109293 | 0.89 | CD4 (0.89) | CD4SORT1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4103052 | 0.88 | CD4 (0.88) | CD4SORT1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL21361470 | 0.88 | CD4 (0.86) | CD4SORT1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4114419 | 0.86 | CD4 (0.84) | CD4SORT1TSHRALDH1A1LMNA | |
| SCHEMBL13925192 | 0.85 | CD4 (0.81) | CD4SORT1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4274368 | 0.85 | CD4 (0.81) | CD4SORT1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4114397 | 0.85 | CD4 (0.80) | CD4SORT1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL13925218 | 0.84 | CD4 (0.80) | CD4SORT1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4113774 | 0.84 | CD4 (0.80) | CD4SORT1TSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048222-A1 | Triaza Compound Immunoregulatory Agents | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048222-A1 | Triaza Compound Immunoregulatory Agents | CD4, NFATC1, IKZF3 | CD4 1/4885SORT1 4792/4885TSHR 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.